Clinical Trials

MainTitle

HIV Prevention Preparedness Study in Russia, China, and India

This study has been completed
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)

Information provided by (Responsible Party)
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier
NCT00021775

First received: August 4, 2001
Last updated: December 31, 2013
Last Verified: December 2013
History of Changes
Purpose

Purpose

The purpose of this study is to set up a system for doing research on HIV prevention in various parts of the world.

In order to plan large, long-term studies on the prevention of HIV in different areas of the world, it is necessary to get certain information first. It is important to know about the rate of HIV infection and how to get people to enroll for any future studies. This study will be done at 4 study locations.

Condition
HIV Infections

Study Type: Observational
Official Title: HIV Prevention Preparedness Study

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Enrollment: 2000
Study Start Date: April 2002
Study Completion Date: February 2004

Detailed Description:

In order to realistically plan for future Phase III studies on HIV prevention, information must be obtained to characterize study population parameters at HTPN sites. Very different study designs may be required depending on these parameters, such as the ability of HPTN research centers to recruit study participants and the rate of HIV incidence observed in study populations. This study will be conducted at 4 HPTN sites to establish the necessary research knowledge and infrastructure.
This study enrolls participants from St. Petersburg, Russia; Xinjiang and Guangxi, China; and Chennai, India who are at high risk for HIV infection due to sexual and/or drug use behaviors. Participants who meet the screening criteria then complete an HIV risk assessment interview, receive HIV pre-test and risk reduction counseling, and undergo phlebotomy for HIV antibody testing. Participants who test positive are referred to available services and studies. Those who test HIV-negative and meet eligibility criteria are enrolled and maintained in follow-up over the next 12 months. Participants complete "locator contacts" at Months 3 and 9 and have follow-up visits at Months 6 and 12 for similar tests as performed at entry. In a substudy of this trial in China, participants will be interviewed about their drug use, social networks, needs, and perceptions about HIV/AIDS. These results will be used by HPTN to design more culturally sensitive and appropriate trials in the future.

Eligibility

Eligibility

Ages Eligible for Study: 14 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: Yes  

Criteria

Inclusion Criteria
Participants may be eligible for this study if they:

  • Are 16 (Saint Petersburg) or 18 (Xinjiang, Guangxi, and Chennai) years of age or older.
  • Are HIV sero-negative.
  • Are available for 12 months of study participation.
  • Have written consent of parent or legal guardian if under age.
  • Are able and willing to provide information on where they can be located or contacted.
  • Meet specific risk-group requirements, for women at heterosexual risk, for men at heterosexual risk, and for injection drug users.

  • Exclusion Criteria
    Participants will not be eligible for this study if they:
  • Have any mental disorders that would cause a problem with the informed consent or study participation.
  • Have any condition that, in the opinion of the doctor, would interfere with the study.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00021775

Locations

China
Guangxi Ctrs. for Disease Control & Prevention and for HIV/AIDS Prevention & Control CRS
Nanning, Guangxi, China, 530028
Xinjiang Uygar Autonomous Region Ctr. for Disease Control & Prevention, HPTN Project Office
Urumqi, Xinjiang, China, 830011
Russian Federation
St. Petersburg Univ. Biomedical Ctr.
St. Petersburg, Russian Federation, 197110

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)

Investigators

Study Chair: Robert Ryder
More Information

More Information


Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)  
ClinicalTrials.gov Identifier: NCT00021775   History of Changes  
Other Study ID Numbers: HPTN 033  
  10611  
Study First Received: August 4, 2001  
Last Updated: December 31, 2013  

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

Risk Factors
Incidence
Patient Selection
HIV Seronegativity

Additional relevant MeSH terms:
HIV Infections

ClinicalTrials.gov processed this data on March 27, 2020
This information is provided by ClinicalTrials.gov.